IM027-1015 BMS A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Bristol-Myers Squibb Company
Start Date
December 4, 2023
End Date
August 31, 2028
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Bristol-Myers Squibb Company
Start Date
December 4, 2023
End Date
August 31, 2028